Companies
BRAIN Biotech
its BRAINBiocatalysts segment supplies enzymes, microorganisms and ingredients for industrial use alongside CRO activity and production-strain development, and it holds a granted European patent (EP4301852 B1) for the CRISPR-BMC nuclease. The nuclease is active across prokaryotic and eukaryotic organisms — bacteria,…
- Country
- Germany
Commercial
BMC Nuclease (EP4301852 B1)
Coverage
| CN | EU | US | |
|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ |
Regulatorsepa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | €49.6 million (FY 2024/25) | brain-biotech-group.com · brain-biotech.com |
| Headcount | around 280 employees (as of September 2025) | brain-biotech-group.com · brain-biotech.com |
| Production site | Zwingenberg (Germany), Potsdam (Germany), Cardiff (UK), Nieuwkuijk (Netherlands), Büttelborn (Germany), Tampa (USA) | brain-biotech.com |
| Capacity | process scale-up to 10 m3 at Cardiff facility | brain-biotech.com |
| Certification | ISO 9001, ISO 14001, ISO 45001, FSSC 22000, Kosher, Halal, SEDEX membership (varies by site) | brain-biotech-group.com |
| Regulatory approval | Support for EFSA and FDA dossiers; compliance with food/pharma safety standards | brain-biotech.com |
| Funding | Publicly funded projects (EU, BMBF, BMWK, FFG), research tax credits, and potential milestone payments (e.g., up to ~€92M from Akribion, ~€138M from Pharvaris/Royalty Pharma) | seat11a.com · brain-biotech.com |
Independent sources: seat11a.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Strain engineering (synbio CRO) | crop-biotech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.